Cargando…

Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: A case report

BACKGROUND: Recently, immunotherapy has emerged as a promising method for advanced HCC treatment. There are several clinical trials and meta-analyses of immune checkpoint inhibitors and immune cell therapy, but clinical evidence on the combination of these two therapies is lacking. CASE DESCRIPTION:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shao M., Jeng, Long-Bin, Shyu, Woei-Cherng, Chen, Hung-Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	China Medical University 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627209/ https://www.ncbi.nlm.nih.gov/pubmed/37937058 http://dx.doi.org/10.37796/2211-8039.1414

Ejemplares similares

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
por: Liu, Guiyuan, et al.
Publicado: (2022)

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
por: Teng, Chiao-Fang, et al.
Publicado: (2021)

Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma
por: Gan, Yi-Xiu, et al.
Publicado: (2022)

Killing effects of Huaier Granule combined with DC-CIK on nude mice transplanted with colon carcinoma cell line
por: Sun, Wen-Wen, et al.
Publicado: (2017)

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
por: Ma, Yue, et al.
Publicado: (2012)

Role of Insulin-like Growth Factor 1 Receptor Signaling in Stem Cell Stemness and Therapeutic Efficacy
por: Teng, Chiao-Fang, et al.
Publicado: (2018)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

A Next-Generation Sequencing-Based Platform for Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma of Hepatocellular Carcinoma Patients
por: Teng, Chiao-Fang, et al.
Publicado: (2018)

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
por: Wang, Ying, et al.
Publicado: (2015)

Comparative investigation of the effects of specific antigen-sensitized DC-CIK and DC-CTL cells against B16 melanoma tumor cells
por: Ren, Peng-Tao, et al.
Publicado: (2017)

Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Stimulation of DC-CIK with PADI4 Protein Can Significantly Elevate the Therapeutic Efficiency in Esophageal Cancer
por: Liu, Chunyan, et al.
Publicado: (2019)

Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine
por: Lin, Syuan-Ling, et al.
Publicado: (2022)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors
por: Feng, Tao, et al.
Publicado: (2022)

Effects of MICA Expression on the Prognosis of Advanced Non-Small Cell Lung Cancer and the Efficacy of CIK Therapy
por: Chen, Yu, et al.
Publicado: (2013)

Increased infiltration of regulatory T cells in hepatocellular carcinoma of patients with hepatitis B virus pre-S2 mutant
por: Teng, Chiao-Fang, et al.
Publicado: (2021)

Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
por: Liu, Zhaonan, et al.
Publicado: (2019)

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)

Next-Generation Sequencing-Based Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma Predicts Hepatocellular Carcinoma Recurrence
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Retracted: Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors
por: Neuroscience, Computational Intelligence and
Publicado: (2022)

DC-CIK biotherapy for a recurrent benign lymphoepithelial lesion of the salivary gland: A case report and literature review
por: XING, DEJUN, et al.
Publicado: (2014)

Cbx7 promotes the generation of induced pluripotent stem cells
por: Wang, Chie-Hong, et al.
Publicado: (2023)

Stem cell–nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy
por: Lai, Yen-Ho, et al.
Publicado: (2023)

Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models
por: Hu, Huanzhang, et al.
Publicado: (2014)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer
por: WANG, YUAN-YUAN, et al.
Publicado: (2013)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma
por: Lai, Hsiang-Chun, et al.
Publicado: (2023)

Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible
por: Ma, Xiaoting, et al.
Publicado: (2023)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
por: Sharma, Amit, et al.
Publicado: (2021)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tqo32sk9it35e2ce002hpcrpaj